TITLE

Review: Thiazolidinediones increase risk for heart failure in type 2 diabetes

PUB. DATE
January 2008
SOURCE
ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p5
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a clinical study that evaluates the risk for heart failure associated with thiazolidinediones in patients with non-insulin-dependent diabetes. The evaluation was conducted on patients with diabetes and heart failure of more than six months. A meta-analysis revealed that the thiazolidinediones increased risk for heart failure in patients with type 2 diabetes.
ACCESSION #
28694424

 

Related Articles

  • COMMENTARY: Review: Thiazolidinediones increase risk for heart failure in type 2 diabetes. Byrne, Christopher D. // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p5 

    The author comments on the meta- analysis concerning the association of thiazolidinediones for heart failures in patients with non-insulin-dependent diabetes. He asserts that the study is useful for practicing health care professionals due to the magnitude of risk is quantified. He pointed out...

  • Prevalence, Incidence and Risk Factors of Chronic Heart Failure in the Type 2 Diabetic Population: Systematic Review. Linuo Zhou; Wei Deng; Lixue Zhou; Ping Fang; Daikun He; Weiwei Zhang; Kui Liu; Renming Hu // Current Diabetes Reviews;2009, Vol. 5 Issue 3, p171 

    Objectives: The aim of this review was to examine the prevalence, incidence and risk factors of chronic heart failure in the type 2 diabetic population. Methods: A systematic search of studies related to chronic heart failure (CHF) in the diabetic population was performed using medical...

  • Thiazolidinediones and Cardiovascular Risk -- A Question of Balance. Erdmann, Erland; Charbonnel, Bernard; Wilcox, Robert // Current Cardiology Reviews;2009, Vol. 5 Issue 3, p155 

    Background: Several recent meta-analyses of adverse event data from randomized controlled trials with rosiglitazone reveal a possible association between this thiazolidinedione and an increased risk of ischemic myocardial events. This has led to debate on the overall clinical benefit of...

  • Effects of Thiazolidinediones Beyond Glycaemic Control. Kalaitzidis, Rigas G.; Sarafidis, Pantelis A.; Bakris, George L. // Current Pharmaceutical Design;2/11/2009, Vol. 15 Issue 5, p529 

    The incidence of type 2 diabetes continues to increase in the western world over the past decade. Consequently, complications of this disease have reached crisis proportions. In addition to the classical oral hypoglycaemic agents, i.e. sulfonylureas, newer classes have emerged that work by...

  • What is the best first-line therapy for type 2 diabetes? Price, Hermione; Cavan, David // Diabetes Digest;2015, Vol. 14 Issue 3, p146 

    The article offers the author's insights as multidisciplinary team members on the published paper regarding the comparative effectiveness patient-centered study on the initial choice for diabetes mellitus oral glucose-lowering treatment. Topics mentioned include the effectiveness of first-line...

  • Heart Failure. Goldberg, Lee R. // Annals of Internal Medicine;6/1/2010, Vol. 152 Issue 11, pITC6-1 

    The article focuses on the prevention, diagnosis, and treatment of heart failure. It discusses risk factors including hypertension and type 2 diabetes mellitus, medications for the prevention of heart failure, the symptoms of heart failure, treatment options and recommendations from professional...

  • Soluble L-Selectin Level Is a Marker for Coronary Artery Disease in Type 2 Diabetic Patients. Albertini, Jean-Paul; Valensi, Paul; Lormeau, Boris; Vaysse, Jenny; Attali, Jean-Raymond; Gattegno, Liliane // Diabetes Care;Dec99, Vol. 22 Issue 12, p2044 

    Presents information on a study which investigated whether the decline in soluble L-selectin level constitutes a marker for mycardial ischemia in type 2 diabetic patients. Account of related studies; Research design and methods; Results and discussion.

  • Risk and Implications of Developing Thiazolidinedione-Related (TZD) CHIC in Patients with Pre-Diabetes (Pre-D) and Type 2 Diabetes (D). Lago, Rodrigo M.; Nesto, Richard W. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA87 

    The magnitude of the clinical benefit in treating hyperglycemia and reducing cardiovascular (CV) risk in pre-D and D patients in some trials evaluating TZDs is difficult to interpret because of the higher incidence of CHF. The outcome and natural history of CHF when due to TZD-related fluid...

  • Insulin For Type 2 Diabetes: Who, When, And Why? Tanenberg, Robert // Diabetes Health;Dec2007/Jan2008, Vol. 16 Issue 6, p34 

    The article discusses the indicators of when to use insulin in type 2 diabetes melitus. Conditions that may render oral anti diabetic drugs ineffective and necessitates insulin administration include serious illnesses, pregnancy, major surgery, congestive heart failure, kidney and liver...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics